Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer

Elio Castagnola, Dimitri Paola, Raffaella Giacchino, Rossella Rossi, Claudio Viscoli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Several antibiotic regimens have been proposed worldwide for empiric treatment of febrile neutropenia in children with cancer, but none of them shows clear advantages in terms of clinical efficacy. Therefore, other parameters, including drug acquisition costs, should be considered in the selection of treatment. Children receive a 'fraction' of a standard daily dose, and this fraction is generally calculated on the basis of body weight; therefore, the cost of each day of therapy is determined by the packages available for each single drug. We calculated the acquisition costs of various drugs proposed for the empiric treatment of febrile neutropenia in children with cancer, and then we estimated the daily cost of therapy referred to different patient weights. In general, the combination regimen with ceftriaxone plus aminoglycoside turned out to be less expensive than other regimens (including monotherapy with third-generation cephalosporins or carbapenems).

Original languageEnglish
Pages (from-to)524-528
Number of pages5
JournalSupportive Care in Cancer
Volume6
Issue number6
DOIs
Publication statusPublished - Nov 1998

Fingerprint

Febrile Neutropenia
Economics
Anti-Bacterial Agents
Drug Costs
Neoplasms
Therapeutics
Costs and Cost Analysis
Carbapenems
Ceftriaxone
Aminoglycosides
Cephalosporins
Body Weight
Weights and Measures
Pharmaceutical Preparations

Keywords

  • Economic evaluation
  • Empiric antibiotic therapy
  • Febrile neutropenia

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. / Castagnola, Elio; Paola, Dimitri; Giacchino, Raffaella; Rossi, Rossella; Viscoli, Claudio.

In: Supportive Care in Cancer, Vol. 6, No. 6, 11.1998, p. 524-528.

Research output: Contribution to journalArticle

Castagnola, Elio ; Paola, Dimitri ; Giacchino, Raffaella ; Rossi, Rossella ; Viscoli, Claudio. / Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. In: Supportive Care in Cancer. 1998 ; Vol. 6, No. 6. pp. 524-528.
@article{ed624f3a70f24d4081da984cf630bd25,
title = "Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer",
abstract = "Several antibiotic regimens have been proposed worldwide for empiric treatment of febrile neutropenia in children with cancer, but none of them shows clear advantages in terms of clinical efficacy. Therefore, other parameters, including drug acquisition costs, should be considered in the selection of treatment. Children receive a 'fraction' of a standard daily dose, and this fraction is generally calculated on the basis of body weight; therefore, the cost of each day of therapy is determined by the packages available for each single drug. We calculated the acquisition costs of various drugs proposed for the empiric treatment of febrile neutropenia in children with cancer, and then we estimated the daily cost of therapy referred to different patient weights. In general, the combination regimen with ceftriaxone plus aminoglycoside turned out to be less expensive than other regimens (including monotherapy with third-generation cephalosporins or carbapenems).",
keywords = "Economic evaluation, Empiric antibiotic therapy, Febrile neutropenia",
author = "Elio Castagnola and Dimitri Paola and Raffaella Giacchino and Rossella Rossi and Claudio Viscoli",
year = "1998",
month = "11",
doi = "10.1007/s005200050208",
language = "English",
volume = "6",
pages = "524--528",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer

AU - Castagnola, Elio

AU - Paola, Dimitri

AU - Giacchino, Raffaella

AU - Rossi, Rossella

AU - Viscoli, Claudio

PY - 1998/11

Y1 - 1998/11

N2 - Several antibiotic regimens have been proposed worldwide for empiric treatment of febrile neutropenia in children with cancer, but none of them shows clear advantages in terms of clinical efficacy. Therefore, other parameters, including drug acquisition costs, should be considered in the selection of treatment. Children receive a 'fraction' of a standard daily dose, and this fraction is generally calculated on the basis of body weight; therefore, the cost of each day of therapy is determined by the packages available for each single drug. We calculated the acquisition costs of various drugs proposed for the empiric treatment of febrile neutropenia in children with cancer, and then we estimated the daily cost of therapy referred to different patient weights. In general, the combination regimen with ceftriaxone plus aminoglycoside turned out to be less expensive than other regimens (including monotherapy with third-generation cephalosporins or carbapenems).

AB - Several antibiotic regimens have been proposed worldwide for empiric treatment of febrile neutropenia in children with cancer, but none of them shows clear advantages in terms of clinical efficacy. Therefore, other parameters, including drug acquisition costs, should be considered in the selection of treatment. Children receive a 'fraction' of a standard daily dose, and this fraction is generally calculated on the basis of body weight; therefore, the cost of each day of therapy is determined by the packages available for each single drug. We calculated the acquisition costs of various drugs proposed for the empiric treatment of febrile neutropenia in children with cancer, and then we estimated the daily cost of therapy referred to different patient weights. In general, the combination regimen with ceftriaxone plus aminoglycoside turned out to be less expensive than other regimens (including monotherapy with third-generation cephalosporins or carbapenems).

KW - Economic evaluation

KW - Empiric antibiotic therapy

KW - Febrile neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0031797848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031797848&partnerID=8YFLogxK

U2 - 10.1007/s005200050208

DO - 10.1007/s005200050208

M3 - Article

C2 - 9833301

AN - SCOPUS:0031797848

VL - 6

SP - 524

EP - 528

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 6

ER -